Randomized phase II clinical trial to evaluate the efficacy of second line FOLFIRI-panitumumab in patients with RAS wild -type metastatic colorectal cancer who have received FOLFOXpanitumumab in first -line (BEYOND)

Filiaciones

Aparicio, J:

Hosp Univ & Politecn La Fe, Serv Oncol Med, Valencia, Spain

Virgili, A:

Hosp Santa Creu & Sant Pau, Barcelona, Spain

Capdevilla, J:

Vall dHebron Hosp, Barcelona, Spain

Boza, FM:

H Univ St Joan Reus, Reus, Spain

Alvarez, R:

Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal HM CIOCC, Madrid, Spain

Univ San Pablo CEU, Dept Ciencias Med Clin, Madrid, Spain

Bosch, C:

Hosp Univ Dr Peset, Valencia, Spain

Camara, I:

H Univ Fundac Alcorcon, Alcorcon, Spain

Fernandez-Martos, C:

Fundac Inst Valenciano Oncol, Valencia, Spain

Fernandez-Plana, J:

Hosp Mutua Terrassa, Terrassa, Spain

Gallego, I:

Hosp Gen Univ Elche, Elche, Spain

Gallego, R:

Hosp Granollers, Granollers, Spain

Hernandez-Vague, X:

Catalan Inst Oncol Girona, Girona, Spain

Declara, IM:

Corp Sanitaria Parc Tauli, Sabadell, Spain

Rodriguez-Salas, N:

Univ Hosp La Paz, Madrid, Spain

Vera, P:

Hosp Navarra, Serv Med Oncol, Pamplona, Spain

Taberner, M:

Hosp La Ribera Alzira Valencia, Alzira, Spain

Maurel, J:

Hosp Clin Barcelona, Barcelona, Spain